{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:03:32Z","timestamp":1771945412076,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.medcli.2025.107288","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:56:01Z","timestamp":1768395361000},"page":"107288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leucemia linfoc\u00edtica cr\u00f3nica doble refractaria: escenarios cl\u00ednicos y opciones terap\u00e9uticas"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-4971","authenticated-orcid":false,"given":"Pablo","family":"Mozas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Quintela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107288_bib0305","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.medcli.2024.10.018","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)","volume":"164","author":"Medina","year":"2025","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2025.107288_bib0310","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0315","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107288_bib0320","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0325","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","author":"Byrd","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0330","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0335","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0340","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0345","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/S2152-2650(24)01259-X","article-title":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"24","author":"Burger","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.medcli.2025.107288_bib0350","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.107288_bib0355","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0360","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0365","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0370","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0375","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0380","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107288_bib0385","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3390\/cancers17142298","article-title":"Chronic lymphocytic leukemia: novel therapeutic targets under investigation","volume":"17","author":"Nayyar","year":"2025","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.medcli.2025.107288_bib0390","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107288_bib0395","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0400","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"JCO."},{"key":"10.1016\/j.medcli.2025.107288_bib0405","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2025.107288_bib0410","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.clml.2022.07.013","article-title":"SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions","volume":"22","author":"Bennett","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2025.107288_bib0415","first-page":"S19","article-title":"Approach to a patient with \u00abdouble refractory\u00bb chronic lymphocytic leukemia: \u00abDouble, double toil and trouble\u00bb (Shakespeare)","volume":"97","author":"Aronson","year":"2022","journal-title":"Am J Hematol."},{"key":"10.1016\/j.medcli.2025.107288_bib0420","doi-asserted-by":"crossref","first-page":"100047","DOI":"10.1016\/j.bneo.2024.100047","article-title":"Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL\/SLL in the United States","volume":"2","author":"Davids","year":"2025","journal-title":"Blood Neoplasia."},{"key":"10.1016\/j.medcli.2025.107288_bib0425","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.medcli.2025.107288_bib0430","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/bloodadvances.2025016006","article-title":"Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia","volume":"9","author":"Yoon","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.medcli.2025.107288_bib0435","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/01.HS9.0000845440.90671.95","article-title":"P639: outcomes for patients with chronic lymphocytic leukemia previously treated with a covalent btk and bcl2 inhibitor in the United States: a real-world database study","volume":"6","author":"Mato","year":"2022","journal-title":"HemaSphere."},{"key":"10.1016\/j.medcli.2025.107288_bib0440","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1182\/blood-2023-187129","article-title":"Clinical outcomes in patients treated with both covalent btkis and venetoclax and the significance of \u00abdouble-refractory\u00bb status in patients with CLL\/SLL","volume":"142","author":"Samples","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0445","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s12672-025-02947-9","article-title":"Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia","volume":"16","author":"Hays","year":"2025","journal-title":"Discov Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0450","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.medcli.2025.107288_bib0455","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2025.107288_bib0460","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood.2024026879","article-title":"Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: the SAKK 34\/17 trial","volume":"145","author":"Condoluci","year":"2025","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0465","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.18357","article-title":"Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia","volume":"199","author":"Hampel","year":"2022","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2025.107288_bib0470","unstructured":"Jacobs R. Wierda W. Barr P.M. et al. Outcomes in high-risk subgroups after fixed-duration ibrutinib +venetoclax for chronic lymphocytic leukemia\/small lymphocytic lymphoma: up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. J Clin Oncol. Disponible en: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420739\/ryan.jacobs.outcomes.in.high-risk.subgroups.after.fixed-duration.ibrutinib.2B.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3D%23p675."},{"key":"10.1016\/j.medcli.2025.107288_bib0475","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1200\/JCO.2025.43.16_suppl.7036","article-title":"Final analysis of fixed-duration ibrutinib +venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study","volume":"43","author":"Ghia","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0480","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0485","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0490","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107288_bib0495","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent bruton tyrosine kinase inhibitor\u2013pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0500","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2016.282","article-title":"Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation","volume":"52","author":"Van Gelder","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medcli.2025.107288_bib0505","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/imj.70050","article-title":"Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era","volume":"55","author":"Barge","year":"2025","journal-title":"Intern Med J."},{"key":"10.1016\/j.medcli.2025.107288_bib0510","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.3390\/cancers15143648","article-title":"Non-covalent bruton's tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia","volume":"15","author":"Montoya","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.medcli.2025.107288_bib0515","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107288_bib0520","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107288_bib0525","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1182\/blood-2022-163596","article-title":"Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1\/2 Dose-Expansion Bellwave-001 study","volume":"140","author":"Woyach","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0530","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and safety of the Bruton's tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0535","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A first-in-human phase 1 trial of nx-2127, a first-in-class Bruton's tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed\/refractory B cell malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0540","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_144","article-title":"144 | Updated efficacy\/safety of the BRUTON tyrosine kinase (BTK) degrader BGB-16673 in relapsed\/refractory (R\/R) CLL\/SLL: results from the ONGOING PHASE 1 CaDAnCe-101 study","volume":"43","author":"Seymour","year":"2025","journal-title":"Hematol Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0545","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): results from CLL expansion and optimization cohorts of Epcore CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0550","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.107288_bib0555","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0560","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature."},{"key":"10.1016\/j.medcli.2025.107288_bib0565","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/bloodadvances.2023011934","article-title":"T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells","volume":"8","author":"Van Bruggen","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.medcli.2025.107288_bib0570","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2024-200339","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0575","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2023-182896","article-title":"Varnimcabtagene Autoleucel (ARI-0001) for relapsed or refractory chronic lymphocytic leukemia (CLL) and Richter transformation (RT)","volume":"142","author":"Ortiz-Maldonado","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0580","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.7036","article-title":"Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study","volume":"43","author":"Ghia","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0585","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0590","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107288_bib0595","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood.2024027460","article-title":"ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"146","author":"Davids","year":"2025","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.107288_bib0600","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1182\/bloodadvances.2023011399","article-title":"Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed\/refractory CLL","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325005160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325005160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:10:33Z","timestamp":1771942233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325005160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0025775325005160"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107288","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leucemia linfoc\u00edtica cr\u00f3nica doble refractaria: escenarios cl\u00ednicos y opciones terap\u00e9uticas","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107288"}}